ANZAC HEALTH AND MEDICAL RESEARCH FOUNDATION

Their core work

The ANZAC Research Institute (ARI) is a biomedical research institute based in Concord, Australia, focused on human health at the intersection of analytical chemistry, molecular biology, and clinical medicine. Their H2020 involvement spans two distinct but complementary areas: advanced optical microscopy of liver endothelial cells (DeLIVER project) and the development of mass spectrometry-based methods for measuring vitamin D metabolites and related biomarkers (OPTIMAL-D project). In both cases, they function as a host institution for European-funded researchers under MSCA schemes, meaning they contribute laboratory infrastructure, domain expertise, and clinical cohort access. Their strength lies in translating analytical method development directly into clinical research applications, particularly around nutritional biomarkers and vascular biology.

What they specialise in

How they've shifted over time

With only two projects spanning 2018-2019, a full longitudinal trajectory is difficult to establish, but a directional shift is visible. The earlier project (DeLIVER, 2018) sits squarely in cell biology and biophysics — super-resolution microscopy of liver fenestrae — with no analytical chemistry emphasis. The subsequent project (OPTIMAL-D, 2019) pivots sharply toward quantitative analytical methods: mass spectrometry, LC-MS/MS, and clinical biomarker measurement. This suggests the institute is broadening from pure cell biology toward applied clinical measurement science, where analytical rigour meets translational health outcomes.

The institute appears to be moving toward quantitative clinical biomarker research, with mass spectrometry as a core methodological platform — making them a relevant partner for any consortium needing validated analytical methods for nutritional or metabolic markers.

How they like to work

ANZAC Research Institute participates exclusively as a third party in MSCA-funded projects, which in practice means they serve as a host organisation for visiting European researchers — providing laboratory access, supervision, and clinical infrastructure rather than leading scientific work packages. This is a non-leading but high-value role: they bring Australian clinical cohorts and specialised equipment that European consortia cannot easily replicate. With 13 unique partners across 8 countries from just 2 projects, they are well-networked relative to their project volume, indicating they are embedded in active international research communities despite their non-European base.

Despite having only two H2020 projects, the institute has built connections with 13 consortium partners across 8 countries, reflecting the broad international consortia typical of MSCA training networks and fellowships. Their geographic reach extends well beyond Australia into European research hubs, primarily through researcher mobility rather than institutional project leadership.

What sets them apart

ANZAC Research Institute occupies a rare position as an Australian clinical research host within European MSCA funding — giving them a role that few Southern Hemisphere institutions fill in H2020 consortia. Their combination of super-resolution microscopy capability (DeLIVER) and clinical-grade mass spectrometry for metabolite analysis (OPTIMAL-D) in the same institute makes them valuable to consortia that need both cell-level mechanistic work and population-level biomarker validation. For a European consortium seeking a non-EU secondment host with real clinical cohort access, ARI is a credible and relatively rare option.

Highlights from their portfolio

• OPTIMAL-D
  Directly addresses the clinically significant and commercially relevant challenge of standardising vitamin D measurement across populations, combining advanced LC-MS/MS method development with real clinical cohort validation — a combination that bridges analytical chemistry and preventive medicine.
• DeLIVER
  Applies super-resolution optical microscopy to liver endothelial fenestrae — a technically demanding niche with direct relevance to drug delivery, liver disease, and aging research — showing the institute's capability in cutting-edge cell imaging infrastructure.